SA520411787B1 - مشتقات بنزيميدازول واستخداماتها - Google Patents

مشتقات بنزيميدازول واستخداماتها

Info

Publication number
SA520411787B1
SA520411787B1 SA520411787A SA520411787A SA520411787B1 SA 520411787 B1 SA520411787 B1 SA 520411787B1 SA 520411787 A SA520411787 A SA 520411787A SA 520411787 A SA520411787 A SA 520411787A SA 520411787 B1 SA520411787 B1 SA 520411787B1
Authority
SA
Saudi Arabia
Prior art keywords
benzimidazole derivatives
compound
present
trpc6
inhibitors
Prior art date
Application number
SA520411787A
Other languages
Arabic (ar)
English (en)
Inventor
مايكل دى بارتبيرجير
جان بانتيليف
هوا جاو
بيريز انجيل جوزمان
وى زهاو
جون ستيلواجين
ناجاسرى شاكا
لاورى شينكيل
ماديلين كيفير
دانيل سى. اتش لين
بينيامين شارليز ميلجرام
زيهاو هوا
بانيل بى هورن
ريان دى ويت
ماثيو ويس
Original Assignee
.امجين انك
تيجين فارما ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by .امجين انك, تيجين فارما ليمتد filed Critical .امجين انك
Publication of SA520411787B1 publication Critical patent/SA520411787B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SA520411787A 2017-10-19 2020-04-17 مشتقات بنزيميدازول واستخداماتها SA520411787B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574465P 2017-10-19 2017-10-19
US201862671090P 2018-05-14 2018-05-14
PCT/US2018/056484 WO2019079578A1 (en) 2017-10-19 2018-10-18 BENZIMIDAZOLE DERIVATIVES AND USES THEREOF

Publications (1)

Publication Number Publication Date
SA520411787B1 true SA520411787B1 (ar) 2022-08-29

Family

ID=66173507

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520411787A SA520411787B1 (ar) 2017-10-19 2020-04-17 مشتقات بنزيميدازول واستخداماتها

Country Status (24)

Country Link
US (1) US11332459B2 (enExample)
EP (1) EP3697410B1 (enExample)
JP (1) JP7450534B2 (enExample)
KR (1) KR102697255B1 (enExample)
CN (1) CN111417394B (enExample)
AU (1) AU2018351059B2 (enExample)
BR (1) BR112020007589A8 (enExample)
CA (1) CA3079081A1 (enExample)
CL (1) CL2020001020A1 (enExample)
CO (1) CO2020004669A2 (enExample)
ES (1) ES3004333T3 (enExample)
HR (1) HRP20250272T1 (enExample)
HU (1) HUE070649T2 (enExample)
IL (1) IL273839B (enExample)
MA (1) MA50413A (enExample)
MX (1) MX2020003993A (enExample)
PH (1) PH12020550265A1 (enExample)
PL (1) PL3697410T3 (enExample)
SA (1) SA520411787B1 (enExample)
SG (1) SG11202003502VA (enExample)
TW (1) TWI816704B (enExample)
UY (1) UY37941A (enExample)
WO (1) WO2019079578A1 (enExample)
ZA (1) ZA202002762B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102732008B1 (ko) 2018-05-14 2024-11-20 길리애드 사이언시즈, 인코포레이티드 Mcl-1 억제제
WO2020210597A1 (en) * 2019-04-11 2020-10-15 Amgen Inc. Benzimidazole derivatives and their uses
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
US11325891B2 (en) 2019-11-26 2022-05-10 Gilead Sciences, Inc. Processes and intermediates for preparing MCL1 inhibitors
MX2022012923A (es) * 2020-04-16 2022-11-16 Boehringer Ingelheim Int Inhibidores de trpc6 para tratar afecciones respiratorias.
AR121846A1 (es) 2020-04-16 2022-07-13 Teijin Pharma Ltd Derivado de arilo o heteroarilo
CN116457334A (zh) 2020-11-19 2023-07-18 吉利德科学公司 用于制备大环mcl1抑制剂的方法和中间体
WO2023276828A1 (ja) * 2021-06-29 2023-01-05 国立大学法人大阪大学 腎障害の予防および／または治療用医薬組成物、並びにオートファジー活性化剤

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2618435B1 (fr) 1987-07-23 1989-10-27 Synthelabo Derives de benzimidazole, leur preparation et leur application en therapeutique
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
DE60140708D1 (de) * 2000-08-10 2010-01-14 Mitsubishi Tanabe Pharma Corp Prolinderivative und deren Verwendung als Medikamente
NZ531679A (en) 2001-10-15 2005-02-25 Janssen Pharmaceutica Nv Novel substituted 4-phenyl-4-[1H-imidazol-2-YL]-piperidine derivatives and their use as selective non-peptide delta opioid agonists
CA2462374C (en) 2001-10-15 2011-01-18 Janssen Pharmaceutica N.V. Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage
CA2494102A1 (en) 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
US7582761B2 (en) * 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
EP1690863A1 (en) * 2003-11-26 2006-08-16 Dainippon Sumitomo Pharma Co., Ltd. Novel condensed imidazole derivative
DE102004017932A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
WO2006010283A1 (en) 2004-07-28 2006-02-02 Universität Zürich Prevention and treatment of thrombus formation
US20100267717A1 (en) 2005-07-29 2010-10-21 4Sc Ag Novel Heterocyclic NF-kB Inhibitors
US7601745B2 (en) 2004-09-27 2009-10-13 4Sc Ag Heterocyclic NF-kB inhibitors
DE102005012875B4 (de) * 2005-03-19 2006-11-16 Sanofi-Aventis Deutschland Gmbh Verwendung von Amino substituierten 8-N-Benzimidazolen
DE102005012874A1 (de) 2005-03-19 2006-09-21 Sanofi-Aventis Deutschland Gmbh Amid substituierte 8-N-Benzimidazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2006108089A1 (en) * 2005-04-06 2006-10-12 North Carolina State University Dense, shaped articles constructed of a refractory material and methods of preparing such articles
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
JP2009510134A (ja) 2005-10-07 2009-03-12 ワラタ ファーマシューティカルズ， インコーポレイテッド Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用
AU2007271243A1 (en) 2006-07-03 2008-01-10 Neurosearch A/S Combinations of monoamine reuptake inhibitors and potassium channel activators
KR20090052884A (ko) 2006-08-23 2009-05-26 화이자 프로덕츠 인크. Ｇｓｋ-3 억제제로서의 피리미돈 화합물
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
WO2008100977A2 (en) 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
WO2008153701A1 (en) * 2007-05-24 2008-12-18 Schering Corporation Compounds for inhibiting ksp kinesin activity
AU2008282295A1 (en) 2007-07-30 2009-02-05 Auspex Pharamaceuticals, Inc. Substituted indoles
US20090176792A1 (en) 2008-01-07 2009-07-09 Auspex Pharmaceuticals, Inc. Substituted dibenzhydrylpiperazines
WO2010104307A2 (ko) 2009-03-07 2010-09-16 주식회사 메디젠텍 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
AU2010259986B2 (en) 2009-06-10 2015-04-02 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
WO2011023812A1 (en) 2009-08-27 2011-03-03 Novasaid Ab Microsomal prostaglandin e synthase-1 (mpges1) inhibitors
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
WO2012098281A2 (es) 2011-01-19 2012-07-26 Universidad Miguel Hernández De Elche Péptidos moduladores de receptores trp y sus usos
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP2698367A1 (en) * 2012-08-14 2014-02-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Benzimidazoles for the treatment of cancer
GB201223265D0 (en) 2012-12-21 2013-02-06 Selvita Sa Novel benzimidazole derivatives as kinase inhibitors
EP2956441A4 (en) 2013-02-18 2016-11-02 Scripps Research Inst MODULATORS OF VASOPRESSIN RECEPTORS WITH THERAPEUTIC POTENTIAL
EP2968536B1 (en) 2013-03-13 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for modulating chemotherapeutic cytotoxicity
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
BR112017001918A2 (pt) 2014-07-31 2017-11-28 Pasteur Institut Korea derivados de 2-amino-benzimidazol e seu uso como inibidores de 5-lipoxigenase e/ou prostaglandina e sintase
TW201643138A (zh) 2015-04-17 2016-12-16 佛瑪治療公司 作為組蛋白脫乙醯基酶（ｈｄａｃ）抑制劑之３－螺－７－異羥肟酸四氫萘
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
GB201603311D0 (en) 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
WO2018039384A1 (en) 2016-08-23 2018-03-01 Ardelyx, Inc. Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators
US10501421B1 (en) * 2017-01-27 2019-12-10 Vanderbilt University Substituted benzimidazoles as modulators of Ras signaling

Also Published As

Publication number Publication date
ES3004333T3 (en) 2025-03-12
US20200308145A1 (en) 2020-10-01
TWI816704B (zh) 2023-10-01
BR112020007589A2 (pt) 2020-09-24
CA3079081A1 (en) 2019-04-25
CN111417394B (zh) 2023-11-07
MX2020003993A (es) 2020-08-13
US11332459B2 (en) 2022-05-17
EP3697410A4 (en) 2021-08-11
CL2020001020A1 (es) 2020-09-21
SG11202003502VA (en) 2020-05-28
HUE070649T2 (hu) 2025-06-28
PL3697410T3 (pl) 2025-04-07
JP7450534B2 (ja) 2024-03-15
KR102697255B1 (ko) 2024-08-23
MA50413A (fr) 2020-08-26
PH12020550265A1 (en) 2021-03-01
AU2018351059B2 (en) 2022-05-12
CO2020004669A2 (es) 2020-05-05
HRP20250272T1 (hr) 2025-04-25
CN111417394A (zh) 2020-07-14
AU2018351059A1 (en) 2020-04-23
IL273839A (en) 2020-05-31
EP3697410C0 (en) 2024-12-18
WO2019079578A1 (en) 2019-04-25
BR112020007589A8 (pt) 2022-08-02
ZA202002762B (en) 2025-03-26
TW201930284A (zh) 2019-08-01
KR20200074965A (ko) 2020-06-25
EP3697410A1 (en) 2020-08-26
IL273839B (en) 2022-09-01
UY37941A (es) 2019-04-30
JP2021500332A (ja) 2021-01-07
EP3697410B1 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
ZA202002762B (en) Benzimidazole derivatives and their uses
PH12018501807A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseas
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
JOP20190174B1 (ar) مثبطات jak1 انتقائية
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
MX2021007247A (es) Derivados de rapamicina.
TN2016000491A1 (en) Carboxamide derivatives.
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
PH12019500327A1 (en) Indazole compounds for use in tendon and/or ligament injuries
AU2018279669A8 (en) Carboxylic acid derivative as at AT2R receptor antagonist
EA202090982A1 (ru) Производные бензимидазола и варианты их применения
MX2022001516A (es) Antagonistas del receptor de neuropeptido ff.
EA201992577A1 (ru) 5,6-конденсированные бициклические соединения и композиции для лечения паразитарных заболеваний
PH12016502247A1 (en) Carboxamide derivatives